Cost-Effectiveness Analysis of Direct Oral Anticoagulants Vs. Vitamin K Antagonists in the Elderly With Atrial Fibrillation: Insights From the Evidence in a Real-World Setting

Background: In the clinical setting, the economic benefits of direct oral anticoagulants (DOACs) in elderly patients with atrial fibrillation (AF) remain unclear. This study aimed to estimate and compare the cost-effectiveness of DOACs (dabigatran, rivaroxaban, apixaban, and edoxaban) and vitamin K...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Yue, Zhang, Chi, Gu, Zhi-Chun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275875/
https://www.ncbi.nlm.nih.gov/pubmed/34268343
http://dx.doi.org/10.3389/fcvm.2021.675200

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275875/
https://www.ncbi.nlm.nih.gov/pubmed/34268343
http://dx.doi.org/10.3389/fcvm.2021.675200

Ejemplares similares